OBJECTIVE: To evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in patients with unresectable locally advanced melanoma. SUMMARY BACKGROUND DATA: Approximately 5% of stage III melanoma patients presents with unresectable locally advanced disease, making standard of care with resection followed by adjuvant systemic therapy impossible. Although neoadjuvant targeted therapy has shown promising results in resectable stage III melanoma, its potency to enable surgical resection in patients with primarily unresectable locally advanced stage III melanoma is still unclear. METHODS: In this prospective, single arm, phase II trial, patients with unresectable BRAF-mutated locally advanced stage IIIC or oligometastatic stage IV melanoma were included. After 8 weeks of treatment with dabrafenib and trametinib, evaluation by PET/CT and physical examination were used to assess sufficient downsizing of the tumor to enable resection. The primary objective was the percentage of patients who achieved a radical (R0) resection. RESULTS: Between August 2014 and March 2019, 21 patients (20/21 stage IIIC AJCC 7th edition) were included. Planned inclusion of 25 patients was not reached due to slow accrual and changing treatment landscape. Despite this, the predefined endpoint was successfully met. In 18/21 (86%) patients a resection was performed, of which 17 were R0 resections. At a median follow-up of 50 months (IQR 37.7- 57.1 months), median recurrence free survival was 9.9 months (95% CI 7.52-not reached) in patients undergoing surgery. CONCLUSIONS: This prospective, single arm, open-label phase II trial, shows neoadjuvant dabrafenib plus trametinib as a potent cytoreductive treatment, allowing radical resection of metastases in 17/21 (81%) patients with prior unresectable locally advanced melanoma.
OBJECTIVE: To evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in patients with unresectable locally advanced melanoma. SUMMARY BACKGROUND DATA: Approximately 5% of stage III melanomapatients presents with unresectable locally advanced disease, making standard of care with resection followed by adjuvant systemic therapy impossible. Although neoadjuvant targeted therapy has shown promising results in resectable stage III melanoma, its potency to enable surgical resection in patients with primarily unresectable locally advanced stage III melanoma is still unclear. METHODS: In this prospective, single arm, phase II trial, patients with unresectable BRAF-mutated locally advanced stage IIIC or oligometastatic stage IV melanoma were included. After 8 weeks of treatment with dabrafenib and trametinib, evaluation by PET/CT and physical examination were used to assess sufficient downsizing of the tumor to enable resection. The primary objective was the percentage of patients who achieved a radical (R0) resection. RESULTS: Between August 2014 and March 2019, 21 patients (20/21 stage IIIC AJCC 7th edition) were included. Planned inclusion of 25 patients was not reached due to slow accrual and changing treatment landscape. Despite this, the predefined endpoint was successfully met. In 18/21 (86%) patients a resection was performed, of which 17 were R0 resections. At a median follow-up of 50 months (IQR 37.7- 57.1 months), median recurrence free survival was 9.9 months (95% CI 7.52-not reached) in patients undergoing surgery. CONCLUSIONS: This prospective, single arm, open-label phase II trial, shows neoadjuvant dabrafenib plus trametinib as a potent cytoreductive treatment, allowing radical resection of metastases in 17/21 (81%) patients with prior unresectable locally advanced melanoma.
Authors: Alexander C J van Akkooi; Tina J Hieken; Elizabeth M Burton; Andrew J Spillane; Merrick I Ross; Charlotte Ariyan; Paolo A Ascierto; Salvatore V M A Asero; Christian U Blank; Matthew S Block; Genevieve M Boland; Corrado Caraco; Sydney Chng; B Scott Davidson; Joao Pedreira Duprat Neto; Mark B Faries; Jeffrey E Gershenwald; Dirk J Grunhagen; David E Gyorki; Dale Han; Andrew J Hayes; Winan J van Houdt; Giorgos C Karakousis; Willem M C Klop; Georgina V Long; Michael C Lowe; Alexander M Menzies; Roger Olofsson Bagge; Thomas E Pennington; Piotr Rutkowski; Robyn P M Saw; Richard A Scolyer; Kerwin F Shannon; Vernon K Sondak; Hussein Tawbi; Alessandro A E Testori; Mike T Tetzlaff; John F Thompson; Jonathan S Zager; Charlotte L Zuur; Jennifer A Wargo Journal: Ann Surg Oncol Date: 2022-01-28 Impact factor: 5.344
Authors: Anna M Czarnecka; Krzysztof Ostaszewski; Aneta Borkowska; Anna Szumera-Ciećkiewicz; Katarzyna Kozak; Tomasz Świtaj; Paweł Rogala; Iwona Kalinowska; Hanna Koseła-Paterczyk; Konrad Zaborowski; Paweł Teterycz; Andrzej Tysarowski; Donata Makuła; Piotr Rutkowski Journal: Cancers (Basel) Date: 2021-12-27 Impact factor: 6.639
Authors: Ahmad A Tarhini; Jennifer R Eads; Kathleen N Moore; Valerie Tatard-Leitman; John Wright; Patrick M Forde; Robert L Ferris Journal: J Immunother Cancer Date: 2022-08 Impact factor: 12.469